TON - February 2013, Vol 6, No 1

The administration of the histone deacetylase inhibitor vorinostat in patients undergoing matched related donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplants could be an effective approach to reducing graft-versus-host disease (GVHD), according to the first-in-human clinical trial of 45 patients. Read More ›

A pooled analysis of the EIN-STEIN-DVT and EINSTEIN-PE studies showed rivaroxaban to be as effective in preventing recurrences of venous thromboembolism as enoxaparin followed by a vitamin-K antagonist, with perhaps less risk for bleeding. Read More ›

The Gibbs Cancer Center, part of the Spartanburg (South Carolina) Regional Healthcare System, is 1 of 21 National Cancer Institute (NCI)-designated community cancer centers. Recognizing in 2007 that 85% of all cancer patients receive their care in the community, NCI set benchmarks for elevating cancer care in the community setting. Read More ›

Surgery and radiation are considered the standard of care for estrogen receptor–negative (ER–) breast cancer. However, adjuvant chemotherapy may have a role in treating isolated ER– breast cancer recurrences, according to results of the Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer (CALOR) trial presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Read More ›

Young women with triple-negative and luminal-type breast cancer were more likely to respond to neoadjuvant chemotherapy than were older women with these cancers, and improved outcomes were observed for young women with luminal-A–like tumors who achieved a pathologic complete response (pCR) versus those who did not. Read More ›

“Sexual and intimacy issues are the white elephant in the room for women with breast cancer,” stated Susan W. Rafte, of the Pink Ribbons Project, Houston, Texas. Read More ›

Colorectal cancer (CRC) is the third most common type of non– ‒skin cancer in both men and women. Read More ›

I spent 8 long months in a city far from my own, undergoing intense chemotherapy and then an autologous stem cell transplant. Read More ›

A 500-mg dose of fulvestrant improved survival compared with a 250-mg dose in women with estrogen receptor–positive (ER+) metastatic breast cancer with no increase in toxicity, according to an update of the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial. Read More ›

Extending tamoxifen treatment for 10 years reduced the risk of dying by 29% compared with the standard 5 years of tamoxifen for estrogen receptor–positive (ER+) breast cancer, but these benefits of longer-duration tamoxifen did not emerge until the second decade after diagnosis, according to results of the international Adjuvant Tamoxifen—Longer Against Shorter (ATLAS) study. Read More ›